|Day Low/High||23.58 / 23.70|
|52 Wk Low/High||19.96 / 25.15|
Animal health and oncology deal activity is heating up in 2017.
Shares of Ariad Pharmaceuticals soared Monday after Japan's Takeda Pharmaceutical offered to buy the leukemia drug maker.
The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.
Data to feature additional insights into vedolizumab and elements of inflammatory bowel disease (IBD)
The SEC has released correspondence between the agency and Valeant over concerns about its tax accounting and non-GAAP reporting measures.
Here's a technical look on how to trade some of the most active stocks on the market today.
Valeant shares fell Wednesday on news that talks with Takeda to take over Valeant's Salix unit have broken down.
Vedolizumab presentations include real-world and post-marketing safety data
In patients with moderate to severely active ulcerative colitis or Crohn's disease, review of real-world data supports outcomes of vedolizumab clinical trial program
Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.
Interim analyses shows clinical benefits with long-term vedolizumab treatment regardless of prior tumor necrosis factor (TNF) antagonist exposure
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
Analysis showed consistent treatment benefit irrespective of prior treatment history with TNF antagonist
Takeda Pharmaceuticals (TKPYY) CEO Christophe Weber said the company is exploring deals outside of Japan, particularly in the U.S.
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
Aims to empower patients with inflammatory bowel disease through unique, Marvel Custom Solutions-illustrated stories featuring a Super Hero with IBD
Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area
Eight abstract presentations include new analyses from the EXAMINE trial and real-world databases
- Myovant to conduct global phase 3 programs of relugolix, a potential best-in-class GnRH antagonist for the treatment of uterine fibroids, endometriosis and prostate cancer
Stocks inch higher by mid-afternoon Friday as Federal Reserve Chair Janet Yellen suggest the central bank could implement another rate hike this summer.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.